TY - JOUR
T1 - The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer
AU - Maharaj, Ashika D.
AU - Evans, Sue M.
AU - Ioannou, Liane J.
AU - Croagh, Daniel
AU - Earnest, Arul
AU - Holland, Jennifer F.
AU - Pilgrim, Charles H.C.
AU - Neale, Rachel E.
AU - Goldstein, David
AU - Kench, James G.
AU - Merrett, Neil D.
AU - White, Kate
AU - Burmeister, Elizabeth A.
AU - Evans, Peter M.
AU - Hayes, Theresa M.
AU - Houli, Nezor
AU - Knowles, Brett
AU - Leong, Trevor
AU - Nikfarjam, Mehrdad
AU - Philip, Jennifer
AU - Quinn, Maddy
AU - Shapiro, Jeremy
AU - Smith, Marty D.
AU - Spillane, John B.
AU - Wong, Rachel
AU - Zalcberg, John R.
PY - 2022
Y1 - 2022
N2 - Background: This study: (i) assessed compliance with a consensus set of quality indicators (QIs) in pancreatic cancer (PC); and (ii) evaluated the association between compliance with these QIs and survival. Methods: Four years of data were collected for patients diagnosed with PC. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). A multivariable analysis tested the relationship between significant patient and hospital characteristics, patient cluster effects within hospitals and survival. Results: 1061 patients were eligible for this study. Significant association with improved survival were: (i) in the potentially resectable group having adjuvant chemotherapy administered following surgery or a reason documented (HR, 0.29; 95 CI, 0.19–0.46); (ii) in the locally advanced group included having chemotherapy ± chemoradiation, or a reason documented for not undergoing treatment (HR, 0.38; 95 CI, 0.25–0.58); and (iii) in the metastatic disease group included having documented performance status at presentation (HR, 0.65; 95 CI, 0.47–0.89), being seen by an oncologist in the absence of treatment (HR, 0.48; 95 CI, 0.31–0.77), and disease management discussed at a multidisciplinary team meeting (HR, 0.79; 95 CI, 0.64–0.96). Conclusion: Capture of a concise data set has enabled quality of care to be assessed.
AB - Background: This study: (i) assessed compliance with a consensus set of quality indicators (QIs) in pancreatic cancer (PC); and (ii) evaluated the association between compliance with these QIs and survival. Methods: Four years of data were collected for patients diagnosed with PC. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). A multivariable analysis tested the relationship between significant patient and hospital characteristics, patient cluster effects within hospitals and survival. Results: 1061 patients were eligible for this study. Significant association with improved survival were: (i) in the potentially resectable group having adjuvant chemotherapy administered following surgery or a reason documented (HR, 0.29; 95 CI, 0.19–0.46); (ii) in the locally advanced group included having chemotherapy ± chemoradiation, or a reason documented for not undergoing treatment (HR, 0.38; 95 CI, 0.25–0.58); and (iii) in the metastatic disease group included having documented performance status at presentation (HR, 0.65; 95 CI, 0.47–0.89), being seen by an oncologist in the absence of treatment (HR, 0.48; 95 CI, 0.31–0.77), and disease management discussed at a multidisciplinary team meeting (HR, 0.79; 95 CI, 0.64–0.96). Conclusion: Capture of a concise data set has enabled quality of care to be assessed.
UR - http://www.scopus.com/inward/record.url?scp=85120166755&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2021.11.005
DO - 10.1016/j.hpb.2021.11.005
M3 - Article
C2 - 34852933
AN - SCOPUS:85120166755
SN - 1365-182X
VL - 24
SP - 950
EP - 962
JO - HPB
JF - HPB
IS - 6
ER -
